Top 50 Organoid Technology in Asia

Forsea utilizes organoid technology to cultivate seafood, specifically targeting endangered species like freshwater eel, to meet the growing demand for sustainable protein sources. This approach enables scalable production that aims for price parity with traditional seafood, addressing the depletion of aquatic ecosystems and the market's unmet needs.

Biodimension develops biofabricated human tissues and organoids for drug and cosmetic safety testing, providing a non-animal alternative that yields more relevant human data. Their technology enhances the drug discovery process by offering customized, three-dimensional tissue models that accurately replicate human biological responses.

ProFuse Technology specializes in muscle cell differentiation, fusion, and maturation through proprietary supplements and immortalized bovine muscle cell lines, enhancing the efficiency of cultivated meat production. Their solutions aim to increase yield, reduce production costs, and accelerate production cycles for life science and cultivated meat companies.

Cellivate provides proprietary cell-based technologies that enhance the growth of animal cells for applications in cultivated meat, skincare, and leather production. By offering cost-effective solutions that integrate into existing workflows, Cellivate addresses the need for sustainable alternatives to traditional animal-derived products.

Integriculture develops a large-scale cellular cultivation technology called the CulNet System, which produces sustainable food products to enhance food security and public health. By providing a marketplace and starter kits for researchers, the company addresses the challenges of traditional agriculture and resource scarcity.

This startup develops RNA technology to reduce the cost of cultivated meat and seafood production. Their technology recycles nutrient media used to grow cultured cells, enabling producers to reuse media and significantly lower production expenses.

Dioseve utilizes Directly Induced Oocyte-like cells (DIOLs) technology to rapidly generate egg-like cells from induced pluripotent stem cells, enabling significant advancements in reproductive health. This approach provides solutions for infertility treatments and the investigation of genetic disorders, addressing critical gaps in current biomedical capabilities.

ALDAVER develops customized surgical training models using biopolymer materials that replicate the mechanical properties of human tissues, combined with 3D printing technology for precise anatomical accuracy. This approach addresses the limitations of traditional training methods, providing a realistic and cost-effective alternative to animal and cadaver-based training environments.

Farcast Biosciences develops the Farcast Human Tumor Microdynamics Platform, which generates multimodal data to model tumor response and resistance to therapies using true-to-human biological systems. This technology enables researchers to identify effective treatment regimens and predict patient responses with greater accuracy, addressing the challenge of personalized cancer therapy.

The startup develops organic semiconductor laser technology that utilizes organic fluorescent materials to create low-cost laser diodes. This technology enables the production of efficient light sources that can be seamlessly integrated into OLED and organic electronic applications, addressing the need for affordable and environmentally friendly lighting solutions.

Organoid Sciences specializes in organoid-based drug discovery and regenerative medicine, utilizing 3D cultured stem cells to create miniaturized organs that closely mimic human tissue. The company addresses the challenge of organ shortages and the need for personalized treatment options for incurable diseases through its advanced drug screening and regenerative therapeutic platforms.

The startup has developed a cell therapy platform that creates Engineered Micro Pancreas (EMP) for pancreatic islet transplantation, providing a viable alternative to traditional insulin therapy. This technology eliminates the need for insulin injections and glucose testing in diabetes patients, significantly improving their quality of life.

The startup develops a medical device that utilizes nanoscale chemical engineering to stimulate cellular growth in the conjunctiva, creating a conducive environment for fibroblast cells to promote healing. This technology aims to treat cornea-related diseases, enabling individuals with corneal blindness to regain their eyesight through the use of implants and implantables.

Cultivates plant-derived micronutrient-rich ingredients using proprietary cell culture technology that selects, enhances, and protects plant cells in sterile, controlled environments. This method reduces agricultural waste, overcomes climate-related limitations, and enables local, scalable production of bioavailable, non-GMO nutrients for food and wellness applications.

This company offers custom 3D bioprinting services and develops specialized bio-inks for research applications. They enable institutions to explore bioprinting for tissue engineering and regenerative medicine without requiring in-house expertise.

Qihan Biotech develops multiplexable gene editing technologies to create immunologically privileged allogenic cells and xenogeneic organs for transplantation. This approach addresses the critical shortage of compatible organ donors and the challenges of organ rejection in transplant patients.

The startup develops cost-effective scaffolding technology specifically for cultivated meat production, enabling companies to replicate the texture and structure of real meat. By providing these scaffolds, the company helps clients reduce reliance on traditional meat sources and lower production costs in the cultivated meat industry.

The startup develops a robotic system that utilizes autonomous movement technology and multi-robot control software to enhance operational efficiency in e-commerce warehouses. This technology reduces labor intensity and increases throughput, addressing the challenges of high demand and workforce limitations in logistics.

Logomix offers a Geno-Writing platform that enables precise engineering of megabase-scale genomic sequences in human cells, facilitating the creation of custom cell types with specific functions. This technology addresses the challenges of immune rejection and functional integration in cell therapies, enhancing the development of advanced regenerative medicine solutions.

The startup manufactures 3D printers and liquid handling systems specifically designed for bioprinting, utilizing proprietary software to optimize cell growth into tissue. By providing consulting services and developing tailored material formulas, the company enhances efficiency in the healthcare sector, addressing the need for more effective tissue engineering solutions.

MeatoLogic develops specialized cells for cellular agriculture using synthetic biology techniques to enhance cell growth and performance in meat production. This technology addresses the challenges of scalability and cost-effectiveness in the foodtech industry, enabling companies to produce cell-based products more efficiently.

The startup develops cell-related therapeutics utilizing induced pluripotent stem cells through cardiomyocyte differentiation and myocardial purification methods with small-molecule compounds. This research enables pre-clinical validation for improved regenerative medicine treatments and cell transplantation procedures.

Alvox Bio provides 3D bioprinting services to create customized tissue models for drug discovery and personalized medicine, utilizing advanced bio-materials and high-throughput in vitro techniques. This technology enables researchers and pharmaceutical companies to evaluate safety, toxicity, and therapeutic potential more accurately, accelerating the development of new therapies.

This startup provides organoid-based drug efficacy and toxicity testing services, offering a cost-effective alternative to animal testing for pharmaceutical companies. Their human-like organoids enable accurate preclinical evaluation of new drug candidates.

REVIVO BioSystems offers 4D human tissue models and organ-on-a-chip platforms for in vitro safety and efficacy testing. Their technology simulates in vivo conditions, including blood flow, to provide more accurate and efficient assessments for chemicals, cosmetics, and pharmaceuticals.

The startup develops optimized parental cells for the production of stem cell exosomes, which have superior proliferation and secretion capabilities. This technology enables mass production of exosomes, providing a scalable solution for targeting incurable diseases.

The startup develops a medical device that enables the contained removal of large internal organs through laparoscopic keyhole incisions using a power morcellator. This technology minimizes the risk of cancerous tissue dispersion during surgery, allowing for safe, minimally invasive organ removal without the complications associated with open surgery.

This startup develops a cell precision control and diagnosis platform that automates massively parallel cellular processes within a single device. The platform enables rapid experimentation and data collection, providing researchers and healthcare providers with efficient workflows for scientific discovery.

Tomocube provides holotomography systems that generate label‑free, quantitative 3D reconstructions of live cells by measuring refractive‑index distributions at sub‑micron resolution. The HT‑X1 platform combines high‑speed optical tomography with AI‑driven segmentation and optional multimodal fluorescence channels, enabling real‑time, high‑throughput imaging of organoids, spheroids, and immune cells for drug screening and regenerative‑medicine research. The companion TomoAnalysis software offers modular, GPU‑accelerated pipelines for volume rendering, phenotype classification, and export in standard data formats.

The startup develops a medical device that utilizes tissue engineering and neuro-modulation technology to treat ophthalmological disorders, specifically targeting dry eye syndrome and eye pain. By mimicking biological signals, the device promotes efficient healing of damaged tissues and nerves, enabling practitioners to effectively manage these conditions.

The startup operates a bio convergence platform that utilizes photosynthetic microalgae for the autonomic culture of animal tissue, eliminating the need for bioreactors in the differentiation, scaffolding, and hypertrophy processes. This approach significantly lowers costs and enhances scalability in cultured meat production.

The startup specializes in cell encapsulation technology that enhances the efficiency of cell mass production for engineering applications. This technology enables clients to utilize cells effectively across various domains, from research to clinical use, by providing a reliable method for handling and processing cells.

Pre-Cure utilizes a multifunctional tumor-on-a-chip platform to enhance the precision of cancer treatment selection by simulating tumor responses in a controlled environment. This technology enables biopharma companies and healthcare providers to tailor therapies based on individual tumor characteristics, improving treatment efficacy and patient outcomes.

Space F develops cell farming technology that utilizes controlled environment agriculture to produce sustainable food products with minimal land use. This method enhances resource efficiency and reduces dependence on conventional farming practices, addressing the critical issues of food security.

Dynomics has developed HeartDyno®, a human cardiac tissue model that enables precision drug discovery by identifying novel therapeutic targets and patient populations for cardiovascular diseases. This platform addresses the lack of well-characterized drug targets and validated therapies in the field of precision cardiology.

Knowledge Palette utilizes whole-genome expression profiling to extract and analyze large-scale data from stem cells, enabling precise control over cellular behavior for regenerative medicine applications. The company addresses the challenges of developing high-quality cell-based therapies for degenerative diseases, which often face variability in manufacturing and unmet medical needs.

Cell in Cells develops cell therapy products utilizing 3D stem cell technology to regenerate damaged tissues and organs. The company addresses the challenges of aging and tissue degeneration by providing solutions that aim to restore biological function and improve quality of life.

The startup develops nerve tissue products and screening technology to identify neurodegenerative diseases, including Amyotrophic Lateral Sclerosis. Their approach includes creating nerve tissue transplants that closely mimic human tissue, enabling targeted treatments for these disorders.

The startup develops a culture technology that focuses on rapidly changing cell therapies and mesenchymal stem cells for treating hypophosphatasia, a rare bone-formation deficiency in newborns, and spinal canal stenosis due to disc herniation. This technology enhances treatment efficacy for these specific medical conditions, providing targeted therapeutic solutions.

The startup develops biomaterials for tissue repair and 3D printing medical devices, providing alternatives to silicone and fillers in reconstructive procedures. Their technology includes advanced molding implants and alternative evaluation models for animal testing, enhancing the efficacy and safety of tissue restoration.

The startup develops clinical-grade human-induced pluripotent stem cells and personalized cell banking services for diabetes treatment. Their offerings enable the application of cell replacement therapies, addressing the need for effective regenerative solutions in diabetes management.

Portrai utilizes AI-driven spatial transcriptomics to improve the accuracy and quality of biopsy samples, enabling detailed tissue characterization. This technology enhances diagnostic precision and supports the development of personalized treatment plans for patients.

RadaHaim has developed a high-throughput organoid assay system that enables the automated production of organoids tailored to specific tumor and cell types for drug screening. This technology addresses the inefficiencies in the drug discovery process by providing accurate disease models that bridge the gap between basic research and clinical trials.

The startup develops bioprinting technologies that enable researchers to create realistic human-like tissues using 3D bioprinting methods. This technology provides a platform for studying human cell behavior in both healthy and disease states, enhancing the understanding of tissue development and pathology.

Cortical Labs develops biological computing systems that integrate lab-grown human neurons with silicon chips to create hybrid computing platforms. This technology enables more efficient data processing and complex problem-solving capabilities, addressing limitations in traditional computing architectures.

Organo-ID develops patient-derived cancer organoids (PDCOs) to predict chemotherapy responses for colorectal carcinoma, utilizing advanced organoid technology to create three-dimensional in vitro disease models. This approach enables healthcare professionals to personalize cancer treatment by assessing drug effectiveness based on individual tumor characteristics.

The startup develops tumoroid-on-a-chip technology utilizing microfluidics and three-dimensional bioprinting to create patient-specific tumor models for pre-clinical drug efficacy testing. This platform enables pharmaceutical companies to evaluate drug responses in a more realistic and predictive manner, improving the accuracy of drug development processes.

The startup develops microRNA-targeted ribonucleic acid and peptide therapeutics that activate stem cells for cell-free tissue regeneration. This technology aims to treat conditions such as cerebral infarction and macular degeneration by promoting tissue repair without the use of live cells.

Plasbio develops AI-driven collaborative robots for automating animal study processes, enhancing efficiency in laboratory research. Their technology addresses the labor-intensive nature of animal research by enabling unmanned operations, thereby increasing throughput and reducing human error.

The startup develops precision medicine technology that profiles multiple biomarkers at the cellular level to characterize tumor microenvironments while preserving localization context and morphology. This approach provides pathologists and oncologists with clinically relevant information to enhance diagnosis, prognosis, and predict drug response.